NK cells serve as a first-line defense and exhibit spontaneous cytolytic activity against tumor cells without the need for neoantigens. Several therapies targeting NK cells have been studied in recent years. However, there are some problems in NK targeted therapy, for example, NK cell activation usually involves the activation of multiple costimulatory molecules, and NK cell-mediated anti-tumor immunity is often hindered by insufficient expression of NK cell-activated ligands and overexpression of MHC I and other coinhibitory molecules on the cancer cells. In the context of the potential of NK-based therapy to advance the field of tumor immunity, establishing a nano-based NK engager development service will be of great significance for cancer treatment.
Fig.1 The Scheme of nanomaterial-based approaches in boosting cancer immunotherapy through NK cells. (Zhan, et al., 2022)
Leveraging years of research on tumor immunity, Creative Biolabs is committed to providing a safe and cost-effective Next™ Nano-based NK Engager Development Service. We used a variety of materially optimized nanoparticle vehicles carrying multiple antibodies with different targets, such as TAA/ costimulatory target-1/ costimulatory target-2 antibody combination formats. On the one hand, the nano-based NK engager recruits and activates NK cells by co-stimulating targets, and on the other hand, it targets tumor cells through the specific TAA target, mediating tumor cell killing through its spontaneous cytolytic activity. At the same time, we also offer a customized nano-based NK engager development service to meet the varying needs of global customers.
Here are some representative published data displays.
Representative data: The researchers established a tri-specific NK cell engager platform that can be successfully developed for EGFR-targeted immunotherapy. The in vitro and in vivo experiments have shown that nano-NK engager with CD16 and 4-1BB stimulating molecules mediated the recruitment and activation of NK cells, targeting and eradicating EGFR-overexpressed tumor cells.
Fig.2 The action scheme of the EGFR-targeted nanoparticle-based tri-specific NK cell engagers (α-EGFR/α-CD16/α-4-1BB NPs) target EGFR-overexpressed cancer cells. (Au, et al., 2020)
Fig. 3. In vitro cytotoxicity of nano-TriNKEs activated NK cells targeting EGFR-overexpressed cancer cells. (Au, et al., 2020)
Q: What are the advantages of Nano-based NK engagers?
A: Nano-based NK engagers development does not require the construction of complex multiple-specific antibodies. In addition, Nano-based NK engagers allow a flexible exchange of chemotherapeutics, targeting moieties for the therapy of different cancer types, and engaging with various immune cell types. While, in terms of mechanism, different from the simple NK engager effect of tri-specific antibodies, it also includes the effect of nanomaterials promoting dsDNA breakage.
For more details about our Next™ Nano-based NK Engager Development Service, please don't hesitate to contact us. We are sincerely looking forward to working with global customers.
For Research Use Only | Not For Clinical Use
Download our brochure